🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Kroger seeks to end deal with Cigna's Express Scripts over drug pricing

Published 09/30/2022, 01:59 PM
Updated 09/30/2022, 02:01 PM
© Reuters. FILE PHOTO: The Kroger supermarket chain's headquarters is shown in Cincinnati, Ohio, U.S., June 28, 2018.   REUTERS/Lisa Baertlein/File Photo
ESRX
-
CI
-
KR
-

(Reuters) - Grocery retailer Kroger (NYSE:KR) Co said on Friday it has sent Cigna Corp (NYSE:CI)'s subsidiary Express Scripts (NASDAQ:ESRX) a written notice of its plan to terminate their pharmacy provider agreement for commercial customers due to an "unsustainable" pricing model.

Kroger said it has made several attempts since February to negotiate with the pharmacy benefit manager for a "more equitable and fair contract that lowers cost, increases access, and delivers greater transparency, but there has been little to no progress to date".

© Reuters. FILE PHOTO: The Kroger supermarket chain's headquarters is shown in Cincinnati, Ohio, U.S., June 28, 2018.   REUTERS/Lisa Baertlein/File Photo

Kroger said more than 90% of Kroger Health's customers will not be affected by a termination of the deal, but if a new agreement is not reached by Dec. 31, most Express Scripts' commercial customers won't be able to fill prescriptions at Kroger stores.

Cigna bought Express Scripts in 2018 in a $54-billion deal, creating one of the biggest providers of pharmacy benefits and insurance plans in the United States.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.